Rheumatoid ArthritisPhase 2NCT01393639
Study Comparing Doses Of An Experimental Glucocorticoid Compound To Prednisone And Placebo In Rheumatoid Arthritis
A Phase 2 study testing PF-04171327 and prednisone in people with Rheumatoid Arthritis, run by Pfizer at 93 sites in 18 countries.
Trial summary
The purpose of this study is to compare the safety and efficacy of multiple doses of PF-04171327, an experimental glucocorticoid drug, to prednisone at 5 mg or 10 mg and placebo in the treatment of rheumatoid arthritis. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Rheumatoid Arthritis
- What is being tested?
- PF-04171327 and prednisone
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 323 participants
- Where
- 93 sitesin 18 countries
- Study dates
- 27 Sep 2011to 9 Jun 2014
- Phase
- Phase 2
- Are there results?
- Yes, posted in the registrySummary in the doctors' view
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Subjects must have documented rheumatoid arthritis with a duration of at least 3 months as determined by the investigator using standardly accepted criteria, must have been receiving methotrexate for at least 3 months to treat their rheumatoid arthritis, and must be free of any signs or symptoms of infection.
Who cannot join
- Subjects cannot enter the study if they have recently received treatment with certain medications which might interfere with study medications;
- subjects cannot enter if they have abnormalities in certain blood tests, history of cancer, recent bone fracture or other significant conditions.
Trial locations and contacts
93 sites in 18 countries.
93 sites in 18 countries
Russia18 sites
Territorial Clinical Hospital
Barnaul, 656024
GBUZ of Kemerovo region Regional clinical hospital for was veterans
Kemerovo, 650000
Kemerovo Regional Clinical Hospital
Kemerovo, 650066
FSBI Scientific - Research Institute of Rheumatology RAMS n.a. V.A. Nasonova.
Moscow, 115522
LLC Consultative and Diagnostic Rheumatological Center Healthy Joints
Novosibirsk, 630091
GBOU VPO "Orenburg State Medical Academy of Ministry of Healthcare of Russian Federation"
Orenburg, Russian Federation, 460000
Republican Hospital V.A.Baranov
Petrozavodsk, 185019
Ryazan Regional Clinical Cardiological Dispensary
Ryazan, 390026
Clinical Rheumatological Hospital #25
Saint Petersburg, 190068
Clinical Hospital #122 L.G. Sokolov
Saint Petersburg, 194291
MUZ City Clinical Hospital #12
Saratov, 410039
Smolensk Regional Clinical Hospital
Smolensk, 214018
Tomsk Regional Clinical Hospital
Tomsk, 634063
Vladimir Regional Clinical Hospital
Vladimir, 600023
Clinical Hospital of Emergency Care N.V. Soloviev
Yaroslavl, 150003
Yaroslavl Regional Clinical Hospital
Yaroslavl, 150062
Sverdlovsk Regional Clinical Hospital # 1
Yekaterinburg, 620102
Municilap Institution Central Clinical Hospital 6
Yekaterinburg, 620149
United States14 sites
Arthritis and Osteoporosis Medical Associates, PLLC
Brooklyn, New York, 11201
Low Country Rheumatology, PA
Charleston, South Carolina, 29406
Tricounty Radiology
Charleston, South Carolina, 29406
Cincinnati Rheumatic Disease Study Group, Inc.
Cincinnati, Ohio, 45219
Allergy, Asthma, Arthritis, and Lung Center
Daytona Beach, Florida, 32114
Altoona Center for Clinical Research
Duncansville, Pennsylvania, 16635
Accurate Clinical Research, Inc.
Houston, Texas, 77034
Javed Rheumatology Associates, Inc.
Newark, Delaware, 19713
Millennium Research
Ormond Beach, Florida, 32174
C. Michael Neuwelt, MD, Inc.
San Leandro, California, 94578
Arthritis Northwest, PLLC
Spokane, Washington, 99204
Catalina Pointe Clinical Research, Inc.
Tucson, Arizona, 85704
Alastair C. Kennedy, MD
Vero Beach, Florida, 32960
The Center for Arthritis and Rheumatism
Vero Beach, Florida, 32960
Ukraine9 sites
Municipal Medical Institution "City Clinical Hospital #3"
Chernivtsi, 58022
Municipal Medicoprophylactic Institution "Donetsk City Clinical Hospital #5".
Donetsk, 83001
National Scientific Centre "Institute of Cardiology n.a. M.D. Strazheska of NAMS of Ukraine".
Kiev, 03680
Komunalnyi zaklad Kyivskoi oblasnoi rady "Kyivska oblasna klinichna likarnia"
Kyiv, 04107
Komunalnyi zaklad Lvivskoi oblasnoi rady "Lvivskyi oblasnyi klinichnyi diahnostychnyi tsentr"
Lviv, 79010
Komunalna ustanova "Odeska oblasna klinichna likarnia"
Odesa, 65025
Municipal Establishment "City Clinical Hospital #9 n.a. O.I. Minakov", Department of Rheumatology
Odesa, 65026
Vinnytsya regional clinical hospital named after M.I. Pyrogova; Department of rheumatology
Vinnytsia, 21018
Municipal Institution:"Zaporizhzhya Regional Clinical Hospital",Rheumatology Dep.
Zaporizhzhya, 69600
Hungary6 sites
Dr. Rethy Pal Korhaz es Rendelointezet, II. Reumatologia Szakrendeles
Békéscsaba, 5600
Budai Irgalmasrendi Korhaz, Reumatologia I.
Budapest, 1027
Revita Reumatologiai Rendelo
Budapest, 1027
Qualiclinic Kft.
Budapest, 1036
Fejer Megyei Szent Gyorgy Korhaz Reumatologia
Székesfehérvár, 8000
MAV Korhaz es Rendelointezet, Reumatologiai szakrendeles
Szolnok, 5000
Slovakia5 sites
AAGS, s.r.o. , nestatne zdravotnicke zariadenie
Dunajská Streda, 92901
Nestatna reumatologicka ambulancia
Považská Bystrica, 017 01
Reumatologicka ambulancia, REUMEX, s.r.o.
Rimavská Sobota, 979 01
Reumaglobal s.r.o.
Trnava, 917 01
Nestatna reumatologicka ambulancia
Žilina, 010 01
South Korea5 sites
Daegu Catholic University Medical Center, Department of Rheumatology
Daegu, 705-718
Inha University Hospital, Medicine/Rheumatology
Incheon, 400-711
KyungHee University Hospital
Seoul, Korea, 130-872
Seoul National University Hospital, Rheumatology, Internal Medicine
Seoul, 110-744
Konkuk University Medical Center, Department of Rheumatology
Seoul, 143-729
Bulgaria4 sites
Revmatologichen kabinet, DKTs Sv. Pantaleimon OOD
Pleven, 5800
Revmatologichno Otdelenie, MBAL - Plovdiv
Plovdiv, 4000
MBAL "Sveti Ivan Rilski" Sofia; Klinika po Revmatologia
Sofia, 1612
MBAL Sveti Ivan Rilski Sofia; Klinika po Revmatologia
Sofia, 1612
Colombia4 sites
Centro Integral de Reumatologia e Inmunologia CIREI
Bogota, Cundinamarca, 110221
Preventive Care SAS
Chía, Cundinamarca, 250001
Hospital Pablo Tobon Uribe
Medellín, Antioquia
Reumalab S.A.S
Medellín, Antioquia
Czechia4 sites
Revmatologie Bruntal, S.R.O.
Bruntál, 79201
Revmatologicka ambulance
Ostrava - Poruba, 70800
Revmatologicka ambulance
Prague, 140 00
Thomayerova nemocnice
Prague, 140 59
Romania4 sites
Spitalul Clinic "Sfanta Maria", Clinica de Medicina Interna si Reumatologie
Bucharest, 800578
Spitalul Clinic Judetean de Urgenta "Sfantul Apostol Andrei"
Galati, 800578
Spitalul Clinic de Recuperare
Iași, 700656
Spitalul Clinic Judetean de Urgenta Targu Mures, Reumatologic
Tg Mures, 540136
Germany3 sites
Charite Universitaetsmedizin Berlin, Klinik fuer Rheumatologie
Berlin, 10117
Klinische Forschung Berlin-Buch GmbH
Berlin, 13125
CIRI GmbH
Frankfurt am Main, 60528
India3 sites
Shirdi Sai Hospital
Bangalore, Karnataka, 560 054
Dapartment of Rheumatology
Lucknow, Uttar Pradesh, 226 018
Krishna Institute of Medical Sciences Ltd
Secunderabad, Andhra Pradesh, 500 003
Mexico3 sites
Centro de Estudios de Investigacion Basica y Clinica SC.
Guadalajara, Jalisco, 44690
Unidad de Investigacion Biomedica del CEM
Mérida, Yucatán, 97000
Centro de Alta Especialidad en Reumatologia e Investigacion del Potosi S.C.
San Luis Potosí City, 78200
Poland3 sites
Centrum Kliniczno-Badawcze J. Brzezicki, B. Górniakiewicz-Brzezicka Lekarze Spółka Partnerska
Elblag, 82-300
Nzoz "Lecznica Mak-Med S.C."
Nadarzyn, 05-830
Wojewodzki Zespol Reumatologiczny im. dr J. Titz-Kosko
Sopot, 81-759
Malaysia2 sites
Hospital Raja Permaisuri Bainun
Ipoh, Perak, 30990
Sunway Medical Centre
Petaling Jaya, Selangor, 46150
Serbia2 sites
Institute of Rheumatology
Belgrade, 11000
Institute for treatment and rehabilitation Niska Banja
Niška Banja, 18205
South Africa2 sites
Panorama Medical Centre
Panorama, Cape Town, 7500
Emmed Research
Pretoria, Gauteng, 0084
Spain2 sites
Complejo Hospitalario Universitario A Coruña. Hospital Materno Infantil Teresa Herrera
A Coruña, 15006
Hospital SANITAS CIMA.
Barcelona, 08034
About this study
Official title: A PHASE 2, RANDOMIZED, DOUBLE BLIND ASSESSMENT OF EFFICACY AND SAFETY OF PF 04171327(1, 5, 10, 15 MG DOSE, DAILY) COMPARED TO 5 MG AND 10 MG PREDNISONE DAILY AND PLACEBO DAILY IN SUBJECTS WITH RHEUMATOID ARTHRITIS OVER AN 8 WEEK PERIOD FOLLOWED BY A 4 WEEK PERIOD OF TAPERING OF STUDY DRUG.
The purpose of this study is to compare the safety and efficacy of multiple doses of PF-04171327, an experimental glucocorticoid drug, to prednisone at 5 mg or 10 mg and placebo in the treatment of rheumatoid arthritis. All subjects will also be receiving background treatment of methotrexate for their rheumatoid arthritis. Study medication will be given for eight weeks followed by a 4 week period during which the dose of study medication will be gradually reduced. The efficacy of the study medications will be determined by assessing severity of the rheumatoid arthritis during the study and safety will be determined by adverse event reporting, laboratory tests and biomarker analysis.
- Conditions
- Rheumatoid Arthritis
- Being tested
- PF-04171327, prednisone, placebo
- Keywords
- treatment of rheumatoid arthritis, treatment of RA, patients on methotrexate for rheumatoid arthritis, prednisone for rheumatoid arthritis
- Medical subject headings
- Arthritis, Rheumatoid
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
PF-04171327Drug
1 mg tablet once daily (QD) for 8 weeks
PF-04171327Drug
5 mg tablet once daily (QD) for 8 weeks
PF-04171327Drug
10 mg tablet once daily (QD) for 8 weeks
PF-04171327Drug
15 mg tablet once daily (QD) for 8 weeks
prednisoneDrug
5 mg capsule once daily for 8 weeks
prednisoneOther
10 mg capsule once daily for 8 weeks
placeboOther
placebo (tablet or capsule) once daily (QD) for 8 weeks
| Study group | Role | What they receive |
|---|---|---|
| PF-04171327 1 mg QD | Experimental | Not described Receives: Drug: PF-04171327 |
| PF-04171327 5 mg QD | Experimental | Not described Receives: Drug: PF-04171327 |
| PF-04171327 10 mg QD | Experimental | Not described Receives: Drug: PF-04171327 |
| PF-04171327 15 mg QD | Experimental | Not described Receives: Drug: PF-04171327 |
| prednisone 5 mg QD | Active comparator | Not described Receives: Drug: prednisone |
| prednisone 10 mg QD | Active comparator | Not described Receives: Other: prednisone |
| placebo | Placebo comparator | Not described Receives: Other: placebo |
What is being measured
The primary outcome is the main question the study is designed to answer.
Percentage of Participants Achieving a 20% Improvement in American College of Rheumatology (ACR) Criteria at Week 8
ACR20 response: greater than or equal to (≥) 20 percent (%) improvement in tender joint count; ≥ 20% improvement in swollen joint count; and ≥ 20% improvement in at least 3 of 5 remaining ACR core measures: participant assessment of pain; participant global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the Health Assessment Questionnaire [HAQ]); and C-Reactive Protein (CRP).
Measured: Week 8
Mean Percent Change From Baseline in 0 Hour Procollagen Type 1 N Terminal Propeptide (P1NP) at Week 8 (Comparisons to Prednisone 5 mg)
Change from baseline in P1NP at week 8 is presented in this outcome measure.
Measured: Week 8
Mean Percent Change From Baseline in 0 Hour Urinary N Telopeptide/Urinary Creatinine (uNTx/uCr) at Week 8 (Comparisons to Prednisone 5 mg)
Change from baseline in uNTx/uCr at week 8 is presented in this outcome measure.
Measured: Week 8
Secondary outcomes (25)
Percentage of Participants Achieving ACR20 Response at Weeks 2, 4, and 12 (Comparisons to Placebo, and Prednisone 10 mg)
ACR20 response: greater than or equal to (≥) 90 percent (%) improvement in tender or swollen joint counts and 90% improvement in 3 of the following 5 criteria: 1) physician's global assessment of disease activity, 2) participant's assessment of disease activity, 3) participant's assessment of pain, 4) participant's assessment of functional disability via a health assessment questionnaire, and 5) C-reactive protein at each visit.
Measured: Weeks 2, 4, and 12 (taper period)
Percentage of Participants Achieving ACR50 Response at Weeks 2, 4, 6, 8 and 12 (Comparisons to Placebo, and Prednisone 10 mg)
ACR50 response: greater than or equal to (≥) 50 percent (%) improvement in tender or swollen joint counts and 50% improvement in 3 of the following 5 criteria: 1) physician's global assessment of disease activity, 2) participant's assessment of disease activity, 3) participant's assessment of pain, 4) participant's assessment of functional disability via a health assessment questionnaire, and 5) C-reactive protein at each visit.
Measured: Weeks 2, 4, 6, 8, and 12 (taper period)
Percentage of Participants Achieving ACR70 Response at Weeks 2, 4, 6, 8 and 12 (Comparisons to Placebo, and Prednisone 10 mg)
ACR70 response: greater than or equal to (≥) 70 percent (%) improvement in tender or swollen joint counts and 70% improvement in 3 of the following 5 criteria: 1) physician's global assessment of disease activity, 2) subject's assessment of disease activity, 3) subject's assessment of pain, 4) subject's assessment of functional disability via a health assessment questionnaire, and 5) C-reactive protein at each visit.
Measured: Weeks 2, 4, 6, 8, and 12 (taper period)
Change From Baseline in Tender-Joint Counts at Weeks 2, 4, 6, 8 (Comparisons to Placebo, and Prednisone 10 mg)
Twenty-eight tender/painful joint count included the following joints: shoulders, elbows, wrists, metacarpophalangeal joints, proximal interphalangeal joints, and knees. Artificial joints were not assessed. These joints were assessed by a joint assessor, who was blinded to the participant's safety data, previous efficacy data and treatment randomization, to determine the number of joints that were considered tender or painful, and swollen.
Measured: Weeks 2, 4, 6, and 8
Change From Baseline in Tender-Joint Counts at Week 12 (Descriptive Statistics)
Twenty-eight tender/painful joint count included the following joints: shoulders, elbows, wrists, metacarpophalangeal joints, proximal interphalangeal joints, and knees. Artificial joints were not assessed. These joints were assessed by a joint assessor, who was blinded to the participant's safety data, previous efficacy data and treatment randomization, to determine the number of joints that were considered tender or painful, and swollen.
Measured: Week 12
Change From Baseline in Swollen-Joint Counts at Weeks 2, 4, 6, and 8 (Comparisons to Placebo, and Prednisone 10 mg)
Twenty-eight tender/painful joint count included the following joints: shoulders, elbows, wrists, metacarpophalangeal joints, proximal interphalangeal joints, and knees. Artificial joints were not assessed. These joints were assessed by a joint assessor, who was blinded to the participant's safety data, previous efficacy data and treatment randomization, to determine the number of joints that were considered tender or painful, and swollen.
Measured: Weeks 2, 4, 6, and 8
Change From Baseline in Swollen-Joint Counts at Week 12 (Descriptive Statistics)
Twenty-eight tender/painful joint count included the following joints: shoulders, elbows, wrists, metacarpophalangeal joints, proximal interphalangeal joints, and knees. Artificial joints were not assessed. These joints were assessed by a joint assessor, who was blinded to the participant's safety data, previous efficacy data and treatment randomization, to determine the number of joints that were considered tender or painful, and swollen.
Measured: Week 12
Change From Baseline in C Reactive Protein (CRP) at Weeks 2, 4, 6, and 8 (Comparisons to Placebo and Prednisone 10 mg)
The CRP was collected at each applicable clinic visit and analyzed by a central laboratory. In order to assist with the data clean-up at the end of the study, the CRP results were unblinded to the sponsor at the time of the last subject's last visit. All statistics presented below are derived from mixed model with fixed effects for treatment, visit, treatment-by-visit interaction and baseline value; unstructured covariance matrix was used.
Measured: Weeks 2, 4, 6, and 8
Change From Baseline of CRP at Week 12 (Descriptive Statistics)
The CRP was collected at each applicable clinic visit and analyzed by a central laboratory. In order to assist with the data clean-up at the end of the study, the CRP results were unblinded to the sponsor at the time of the last subject's last visit.
Measured: Week 12
Change From Baseline in Patient Global Assessment of Arthritis at Weeks 2, 4, 6, and 8 (Comparisons to Placebo, and Prednisone 10 mg)
Participants answered the following question, "Considering all the ways your arthritis affects you, how are you feeling today?" The subject's response was recorded using a 100 mm Visual Analog Scale (VAS), where 0 mm = no pain and 100 mm = most severe pain.
Measured: Weeks 2, 4, 6, and 8
Change From Baseline in Patient Global Assessment of Arthritis at Week 12 (Descriptive Statistics)
Participants answered the following question, "Considering all the ways your arthritis affects you, how are you feeling today?" The subject's response was recorded using a 100 mm Visual Analog Scale (VAS), where 0 mm = no pain and 100 mm = most severe pain.
Measured: Week 12
Change From Baseline in Physician Global Assessment of Arthritis at Weeks 2, 4, 6, and 8 (Comparisons to Placebo, and Prednisone 10 mg)
The investigator assessed how the participant's overall arthritis appears at the time of the visit. This was an evaluation based on the participant's disease signs, functional capacity and physical examination, and was independent of the Patient's Global Assessment of Arthritis. The investigator's response was recorded using a 100 mm VAS, where 0 mm = no pain and 100 mm = most severe pain.
Measured: Weeks 2, 4, 6, and 8
Change From Baseline in Physician Global Assessment of Arthritis at Week 12 (Descriptive Statistics)
The investigator assessed how the participant's overall arthritis appears at the time of the visit. This was an evaluation based on the participant's disease signs, functional capacity and physical examination, and was independent of the Patient's Global Assessment of Arthritis. The investigator's response was recorded using a 100 mm VAS, where 0 mm = no pain and 100 mm = most severe pain.
Measured: Week 12
Change From Baseline in Pain VAS at Weeks 2, 4, 6, and 8 (Comparisons to Placebo, and Prednisone 10 mg)
Participants assessed the severity of their arthritis pain using a 100 mm VAS placing a mark on the scale between 0 (no pain) and 100 (most severe pain), which corresponds to the magnitude of their pain.
Measured: Weeks 2, 4, 6, and 8
Change From Baseline in Pain VAS at Week 12 (Descriptive Statistics)
Participants assessed the severity of their arthritis pain using a 100 mm VAS placing a mark on the scale between 0 (no pain) and 100 (most severe pain), which corresponds to the magnitude of their pain.
Measured: Week 12
Change From Baseline in HAQ-DI at Weeks 2, 4, 6, and 8 (Comparisons to Placebo, and Prednisone 10 mg)
Health Assessment Questionnaire-Disability Index (HAQ-DI): participant-reported assessment of ability to perform tasks in 8 categories of daily living activities: dress/groom; arise; eat; walk; reach; grip; hygiene; and common activities over past week. Each item scored on 4-point scale from 0 to 3: 0=no difficulty; 1=some difficulty; 2=much difficulty; 3=unable to do. Overall score was computed as the sum of domain scores and divided by the number of domains answered. Total possible score range 0-3 where 0 = least difficulty and 3 = extreme difficulty.
Measured: Weeks 2, 4, 6, and 8
Change From Baseline in HAQ-DI at Week 12 (Descriptive Statistics)
Health Assessment Questionnaire-Disability Index (HAQ-DI): participant-reported assessment of ability to perform tasks in 8 categories of daily living activities: dress/groom; arise; eat; walk; reach; grip; hygiene; and common activities over past week. Each item scored on 4-point scale from 0 to 3: 0=no difficulty; 1=some difficulty; 2=much difficulty; 3=unable to do. Overall score was computed as the sum of domain scores and divided by the number of domains answered. Total possible score range 0-3 where 0 = least difficulty and 3 = extreme difficulty.
Measured: Week 12
Change From Baseline in Disease Activity Score (DAS) 28-3 CRP at Weeks 2, 4, 6, and 8 (Comparisons to Placebo, and Prednisone 10 mg)
DAS28-3 (CRP) was calculated from the SJC and TJC using the 28 joints count and CRP (mg/L). Total score range: 0 to 9.4, higher score indicated more disease activity. DAS28-3 (CRP) <= 3.2 implied low disease activity and >3.2 to 5.1 implied moderate to high disease activity, and DAS28-3 (CRP) <2.6 = remission.
Measured: Weeks 2, 4, 6, and 8
Change From Baseline in DAS 28-3 CRP at Week 12 (Descriptive Statistics)
DAS28-3 (CRP) was calculated from the SJC and TJC using the 28 joints count and CRP (mg/L). Total score range: 0 to 9.4, higher score indicated more disease activity. DAS28-3 (CRP) <= 3.2 implied low disease activity and >3.2 to 5.1 implied moderate to high disease activity, and DAS28-3 (CRP) <2.6 = remission.
Measured: Week 12
Change From Baseline in DAS28-4(CRP) at Weeks 2, 4, 6, and 8 (Comparisons to Placebo, and Prednisone 10 mg)
DAS28-4 (CRP) was calculated from the SJC and TJC using the 28 joints count and CRP (mg/L). Total score range: 0 to 9.4, higher score indicated more disease activity. DAS28-3 (CRP) <= 3.2 implied low disease activity and >3.2 to 5.1 implied moderate to high disease activity, and DAS28-3 (CRP) <2.6 = remission. All statistics presented below are derived from mixed model with fixed effects for treatment, visit, treatment-by-visit interaction and baseline value; unstructured covariance matrix was used.
Measured: Weeks 2, 4, 6, and 8
Change From Baseline in DAS28-4(CRP) at Week 12 (Descriptive Statistics)
DAS28-4 (CRP) was calculated from the SJC and TJC using the 28 joints count and CRP (mg/L). Total score range: 0 to 9.4, higher score indicated more disease activity. DAS28-3 (CRP) <= 3.2 implied low disease activity and >3.2 to 5.1 implied moderate to high disease activity, and DAS28-3 (CRP) <2.6 = remission.
Measured: Week 12
Change From Baseline in SF-36v2 Mental Component Scores at Weeks 4 and 8 (Comparisons to Placebo, and Prednisone 10 mg)
The 36 item Short Form Health Survey (SF-36) (Versions 2, acute version) is a 36 item generic health status measure. It measures 8 general health concepts: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role emotional, and mental health. These concepts can also be summarized as physical component score (PCS) and mental component score (MCS). The score for a section is an average of the individual question scores, which are scaled 0-100 (100=highest level of functioning). This questionnaire was completed by the participant prior to any procedures being performed at the visit, if possible. The form was then checked by site staff for completeness.
Measured: Weeks 4 and 8
Change From Baseline in SF-36v2 Mental Component Scores at Week 12 (Descriptive Statistics)
The 36 item Short Form Health Survey (SF-36) (Versions 2, acute version) is a 36 item generic health status measure. It measures 8 general health concepts: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role emotional, and mental health. These concepts can also be summarized as physical component score (PCS) and mental component score (MCS). The score for a section is an average of the individual question scores, which are scaled 0-100 (100=highest level of functioning). This questionnaire was completed by the participant prior to any procedures being performed at the visit, if possible. The form was then checked by site staff for completeness.
Measured: Week 12
Change From Baseline in SF-36v2 Physical Component Scores at Weeks 4 and 8 (Comparisons to Placebo, and Prednisone 10 mg)
The 36 item Short Form Health Survey (SF-36) (Versions 2, acute version) is a 36 item generic health status measure. It measures 8 general health concepts: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role emotional, and mental health. These concepts can also be summarized as physical component score (PCS) and mental component score (MCS). The score for a section is an average of the individual question scores, which are scaled 0-100 (100=highest level of functioning). This questionnaire was completed by the participant prior to any procedures being performed at the visit, if possible. The form was then checked by site staff for completeness.
Measured: Weeks 4 and 8
Change From Baseline in SF-36v2 Physical Component Scores at Week 12 (Descriptive Statistics)
The 36 item Short Form Health Survey (SF-36) (Versions 2, acute version) is a 36 item generic health status measure. It measures 8 general health concepts: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role emotional, and mental health. These concepts can also be summarized as physical component score (PCS) and mental component score (MCS). The score for a section is an average of the individual question scores, which are scaled 0-100 (100=highest level of functioning). This questionnaire was completed by the participant prior to any procedures being performed at the visit, if possible. The form was then checked by site staff for completeness.
Measured: Week 12
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted13 Jul 2011 (estimated)
- Study start27 Sep 2011
- Primary completion3 Jun 2014
- Study completion9 Jun 2014
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Rheumatoid ArthritisStudies of the same condition, open and under way.
- More trials run by PfizerThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 2
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind
- Who is masked
- Participant, Investigator
- Enrolment
- 323 participants (actual)
Sponsor and investigators
- Lead sponsor
- Pfizer
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Pfizer CT.gov Call Center, Study director, Pfizer
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT01393639
- Sponsor's protocol ID
- A9391010
- Other IDs
- 2010-023782-22
- Status last verified
- Aug 2024
- First submitted
- 13 Jun 2011
- Last updated
- 4 Sep 2024
- Results posted
- Yes, on ClinicalTrials.gov
- Data monitoring committee
- Yes
- Individual data sharing
- Yes: Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical\_trials/trial\_data\_and\_results/data\_requests.
Publications
Buttgereit F, Strand V, Lee EB, Simon-Campos A, McCabe D, Genet A, Tammara B, Rojo R, Hey-Hadavi J. Fosdagrocorat (PF-04171327) versus prednisone or placebo in rheumatoid arthritis: a randomised, double-blind, multicentre, phase IIb study. RMD Open. 2019 Apr 16;5(1):e000889. doi: 10.1136/rmdopen-2018-000889. eCollection 2019.
PubMed 31168411
Study at a glance
From the registry record, last updated by the sponsor on 4 Sep 2024. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A PHASE 2, RANDOMIZED, DOUBLE BLIND ASSESSMENT OF EFFICACY AND SAFETY OF PF 04171327(1, 5, 10, 15 MG DOSE, DAILY) COMPARED TO 5 MG AND 10 MG PREDNISONE DAILY AND PLACEBO DAILY IN SUBJECTS WITH RHEUMATOID ARTHRITIS OVER AN 8 WEEK PERIOD FOLLOWED BY A 4 WEEK PERIOD OF TAPERING OF STUDY DRUG.
- ClinicalTrials.gov ID
- NCT01393639
- Acronym / sponsor ID
- A9391010
- Conditions
- Rheumatoid Arthritis
- Keywords
- treatment of rheumatoid arthritis, treatment of RA, patients on methotrexate for rheumatoid arthritis, prednisone for rheumatoid arthritis
- Phase
- Phase 2
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 323 participants (actual)
- Lead sponsor
- PfizerIndustry (pharma, biotech, devices)
- Study start
- 27 Sep 2011 (actual)
- Primary completion
- 3 Jun 2014 (actual)
- Study completion
- 9 Jun 2014 (actual)
- First posted
- 13 Jul 2011 (estimated)
- Results
- Posted 4 Sep 2024
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of this study is to compare the safety and efficacy of multiple doses of PF-04171327, an experimental glucocorticoid drug, to prednisone at 5 mg or 10 mg and placebo in the treatment of rheumatoid arthritis. All subjects will also be receiving background treatment of methotrexate for their rheumatoid arthritis. Study medication will be given for eight weeks followed by a 4 week period during which the dose of study medication will be gradually reduced. The efficacy of the study medications will be determined by assessing severity of the rheumatoid arthritis during the study and safety will be determined by adverse event reporting, laboratory tests and biomarker analysis.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind (participant, investigator)
- Number of arms
- 7
| Arm | Type | Receives |
|---|---|---|
| PF-04171327 1 mg QD | Experimental | Drug: PF-04171327 |
| PF-04171327 5 mg QD | Experimental | Drug: PF-04171327 |
| PF-04171327 10 mg QD | Experimental | Drug: PF-04171327 |
| PF-04171327 15 mg QD | Experimental | Drug: PF-04171327 |
| prednisone 5 mg QD | Active comparator | Drug: prednisone |
| prednisone 10 mg QD | Active comparator | Other: prednisone |
| placebo | Placebo comparator | Other: placebo |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (1 listed)
- Subjects must have documented rheumatoid arthritis with a duration of at least 3 months as determined by the investigator using standardly accepted criteria, must have been receiving methotrexate for at least 3 months to treat their rheumatoid arthritis, and must be free of any signs or symptoms of infection.
Key exclusion criteria (2 listed)
- Subjects cannot enter the study if they have recently received treatment with certain medications which might interfere with study medications;
- subjects cannot enter if they have abnormalities in certain blood tests, history of cancer, recent bone fracture or other significant conditions.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| PF-041713271 mg tablet once daily (QD) for 8 weeks | Drug | PF-04171327 1 mg QD |
| PF-041713275 mg tablet once daily (QD) for 8 weeks | Drug | PF-04171327 5 mg QD |
| PF-0417132710 mg tablet once daily (QD) for 8 weeks | Drug | PF-04171327 10 mg QD |
| PF-0417132715 mg tablet once daily (QD) for 8 weeks | Drug | PF-04171327 15 mg QD |
| prednisone5 mg capsule once daily for 8 weeks | Drug | prednisone 5 mg QD |
| prednisone10 mg capsule once daily for 8 weeks | Other | prednisone 10 mg QD |
| placeboplacebo (tablet or capsule) once daily (QD) for 8 weeks | Other | placebo |
Primary outcome
Percentage of Participants Achieving a 20% Improvement in American College of Rheumatology (ACR) Criteria at Week 8
Time frame: Week 8
ACR20 response: greater than or equal to (≥) 20 percent (%) improvement in tender joint count; ≥ 20% improvement in swollen joint count; and ≥ 20% improvement in at least 3 of 5 remaining ACR core measures: participant assessment of pain; participant global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the Health Assessment Questionnaire [HAQ]); and C-Reactive Protein (CRP).
Mean Percent Change From Baseline in 0 Hour Procollagen Type 1 N Terminal Propeptide (P1NP) at Week 8 (Comparisons to Prednisone 5 mg)
Time frame: Week 8
Change from baseline in P1NP at week 8 is presented in this outcome measure.
Mean Percent Change From Baseline in 0 Hour Urinary N Telopeptide/Urinary Creatinine (uNTx/uCr) at Week 8 (Comparisons to Prednisone 5 mg)
Time frame: Week 8
Change from baseline in uNTx/uCr at week 8 is presented in this outcome measure.
25 secondary outcomes
Percentage of Participants Achieving ACR20 Response at Weeks 2, 4, and 12 (Comparisons to Placebo, and Prednisone 10 mg)
Time frame: Weeks 2, 4, and 12 (taper period)
Percentage of Participants Achieving ACR50 Response at Weeks 2, 4, 6, 8 and 12 (Comparisons to Placebo, and Prednisone 10 mg)
Time frame: Weeks 2, 4, 6, 8, and 12 (taper period)
Percentage of Participants Achieving ACR70 Response at Weeks 2, 4, 6, 8 and 12 (Comparisons to Placebo, and Prednisone 10 mg)
Time frame: Weeks 2, 4, 6, 8, and 12 (taper period)
Change From Baseline in Tender-Joint Counts at Weeks 2, 4, 6, 8 (Comparisons to Placebo, and Prednisone 10 mg)
Time frame: Weeks 2, 4, 6, and 8
Change From Baseline in Tender-Joint Counts at Week 12 (Descriptive Statistics)
Time frame: Week 12
Change From Baseline in Swollen-Joint Counts at Weeks 2, 4, 6, and 8 (Comparisons to Placebo, and Prednisone 10 mg)
Time frame: Weeks 2, 4, 6, and 8
Change From Baseline in Swollen-Joint Counts at Week 12 (Descriptive Statistics)
Time frame: Week 12
Change From Baseline in C Reactive Protein (CRP) at Weeks 2, 4, 6, and 8 (Comparisons to Placebo and Prednisone 10 mg)
Time frame: Weeks 2, 4, 6, and 8
Change From Baseline of CRP at Week 12 (Descriptive Statistics)
Time frame: Week 12
Change From Baseline in Patient Global Assessment of Arthritis at Weeks 2, 4, 6, and 8 (Comparisons to Placebo, and Prednisone 10 mg)
Time frame: Weeks 2, 4, 6, and 8
Change From Baseline in Patient Global Assessment of Arthritis at Week 12 (Descriptive Statistics)
Time frame: Week 12
Change From Baseline in Physician Global Assessment of Arthritis at Weeks 2, 4, 6, and 8 (Comparisons to Placebo, and Prednisone 10 mg)
Time frame: Weeks 2, 4, 6, and 8
Change From Baseline in Physician Global Assessment of Arthritis at Week 12 (Descriptive Statistics)
Time frame: Week 12
Change From Baseline in Pain VAS at Weeks 2, 4, 6, and 8 (Comparisons to Placebo, and Prednisone 10 mg)
Time frame: Weeks 2, 4, 6, and 8
Change From Baseline in Pain VAS at Week 12 (Descriptive Statistics)
Time frame: Week 12
Change From Baseline in HAQ-DI at Weeks 2, 4, 6, and 8 (Comparisons to Placebo, and Prednisone 10 mg)
Time frame: Weeks 2, 4, 6, and 8
Change From Baseline in HAQ-DI at Week 12 (Descriptive Statistics)
Time frame: Week 12
Change From Baseline in Disease Activity Score (DAS) 28-3 CRP at Weeks 2, 4, 6, and 8 (Comparisons to Placebo, and Prednisone 10 mg)
Time frame: Weeks 2, 4, 6, and 8
Change From Baseline in DAS 28-3 CRP at Week 12 (Descriptive Statistics)
Time frame: Week 12
Change From Baseline in DAS28-4(CRP) at Weeks 2, 4, 6, and 8 (Comparisons to Placebo, and Prednisone 10 mg)
Time frame: Weeks 2, 4, 6, and 8
Change From Baseline in DAS28-4(CRP) at Week 12 (Descriptive Statistics)
Time frame: Week 12
Change From Baseline in SF-36v2 Mental Component Scores at Weeks 4 and 8 (Comparisons to Placebo, and Prednisone 10 mg)
Time frame: Weeks 4 and 8
Change From Baseline in SF-36v2 Mental Component Scores at Week 12 (Descriptive Statistics)
Time frame: Week 12
Change From Baseline in SF-36v2 Physical Component Scores at Weeks 4 and 8 (Comparisons to Placebo, and Prednisone 10 mg)
Time frame: Weeks 4 and 8
Change From Baseline in SF-36v2 Physical Component Scores at Week 12 (Descriptive Statistics)
Time frame: Week 12
Results and safety
Loading the posted results from ClinicalTrials.gov…
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 4 Sep 2024.
- Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
- Derived from this study: PubMed 31168411Buttgereit F, Strand V, Lee EB, Simon-Campos A, McCabe D, Genet A, Tammara B, Rojo R, Hey-Hadavi J. Fosdagrocorat (PF-04171327) versus prednisone or placebo in rheumatoid arthritis: a randomised, double-blind, multicentre, phase IIb study. RMD Open. 2019 Apr 16;5(1):e000889. doi: 10.1136/rmdopen-2018-000889. eCollection 2019.
- To obtain contact information for a study center near you, click here.Link provided by the sponsor.
- Individual participant dataSharing planned: Yes. Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Related trials for Rheumatoid Arthritis
RecruitingPhase 2
Study of PTC844 in Participants With Active Rheumatoid Arthritis
Rheumatoid Arthritis
Not yet recruitingPhase 1
An Ascending Dose Study of DKB903 in Participants With Rheumatoid Arthritis (RA) and Participants With Systemic Lupus Erythematosus (SLE)
Rheumatoid Arthritis and Systemic Lupus Erythematosus
Not yet recruitingPhase 1
R-2487 in Patients With Sjogren's Syndrome (SjD)
Sjogren's Syndrome, Sjögren
RecruitingPhase 1
A Trial in Healthy Adult Participants and Adults With Autoimmune Diseases to Test How HBM7020 is Tolerated and How it Behaves in the Body
Rheumatoid Arthritis, Systemic Lupus Erythematosus
Active, not recruitingPhase 2
A Study Evaluating the Safety and Efficacy of Inhaled AP01 in Participants With Progressive Pulmonary Fibrosis
Pulmonary Fibrosis, Progressive Pulmonary Fibrosis
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Pfizer CT.gov Call Center study director
Pfizer
93 sites in 18 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 2 study testing PF-04171327 and prednisone in people with Rheumatoid Arthritis, run by Pfizer at 93 sites in 18 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 4 Sep 2024. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 93 sites in Russia, United States, Ukraine, Hungary, Slovakia and 13 more countries. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
Yes. Results are posted in the registry (first posted 4 Sep 2024). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Percentage of Participants Achieving a 20% Improvement in American College of Rheumatology (ACR) Criteria at Week 8 (time frame: Week 8). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT01393639, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 4 Sep 2024.